UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 16, 2019
REPLIGEN CORPORATION
(Exact name of registrant as specified in charter)
| Delaware | 000-14656 | 04-2729386 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453
(Address of Principal Executive Offices) (Zip Code)
(781)250-0111
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
|
|
| ||
| Common Stock, par value $0.01 per share | RGEN | The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) orRule 12b-2 of the Securities Exchange Act of1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 1.01 | Entry into a Material Definitive Agreement |
Underwritten Public Offering of Common Stock
On July 16, 2019, Repligen Corporation (the “Company”) entered into an underwriting agreement (the “Common Stock Underwriting Agreement”) with J.P. Morgan Securities LLC, Stephens Inc. and Janney Montgomery Scott LLC, as representatives of the underwriters named therein (the “Common Stock Underwriters”), relating to an underwritten public offering (the “Common Stock Offering”) of 1,380,000 shares of the Company’s common stock, $0.01 par value per share (the “Common Stock”), at a price to the public of $87.00 per share (the “Offering Price”). After deducting the underwriting discounts and commissions and estimated offering expenses, the Company expects to receive net proceeds from the Common Stock Offering of approximately $113.6 million. The Company has also granted the Common Stock Underwriters a30-day option to purchase up to an additional 207,000 shares of Common Stock at the Offering Price, less underwriting discounts and commissions.
The Common Stock Offering was made pursuant to the Company’s effective automatic shelf registration statement onForm S-3 (FileNo. 333-231098), including the prospectus dated April 29, 2019, as supplemented by a prospectus supplement dated July 16, 2019, filed on July 17, 2019, and a free writing prospectus dated July 16, 2019, filed on July 17, 2019. The Common Stock Offering is expected to close on or about July 19, 2019, subject to the satisfaction of customary closing conditions.
A copy of the Common Stock Underwriting Agreement is attached as Exhibit 1.1 to this Current Report onForm 8-K and is incorporated herein by reference. The foregoing description of the Common Stock Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.
A copy of the legal opinion of Goodwin Procter LLP relating to the legality of the issuance and sale of the Common Stock in the Common Stock Offering is attached as Exhibit 5.1 to this Current Report onForm 8-K.
Underwritten Public Offering of 0.375% Convertible Senior Notes due 2024
On July 16, 2019, the Company entered into an underwriting agreement (the “Notes Underwriting Agreement”) with J.P. Morgan Securities LLC, as representative of the underwriters named therein (the “Notes Underwriters”), relating to an underwritten public offering (the “Notes Offering”) of $250,000,000 aggregate principal amount of 0.375% Convertible Senior Notes due 2024 (the “Notes”). After deducting the underwriting discounts and commissions and estimated offering expenses, the Company expects to receive net proceeds from the Notes Offering of approximately $242.0 million. The Company has also granted the Notes Underwriters a13-day option to purchase up to an additional $37.5 million aggregate principal amount of Notes solely to cover over-allotments.
The Notes Offering was made pursuant to the Company’s effective automatic shelf registration statement onForm S-3 (FileNo. 333-231098), including the prospectus dated April 29, 2019, as supplemented by a prospectus supplement dated July 16, 2019, filed on July 17, 2019, and a free writing prospectus dated July 16, 2019, filed on July 17, 2019. The Notes Offering is expected to close on or about July 19, 2019, subject to the satisfaction of customary closing conditions.
The Notes will be issued pursuant to a base indenture and a first supplemental indenture, each anticipated to be dated July 19, 2019, to be entered into by and between the Company and Wilmington Trust, National Association, as trustee.
A copy of the Notes Underwriting Agreement is attached as Exhibit 1.2 to this Current Report onForm 8-K and is incorporated herein by reference. The foregoing description of the Notes Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.
A copy of the legal opinion of Goodwin Procter LLP relating to the legality of the issuance and sale of the Notes in the Notes Offering is attached as Exhibit 5.2 to this Current Report onForm 8-K.
| Item 8.01 | Other Events |
On July 15, 2019, the Company issued a press release announcing the commencement of the Common Stock Offering and the Notes Offering. On July 17, 2019, the Company issued a press release announcing the pricing of the Common Stock Offering and the Notes Offering. Copies of these press releases are attached to this Current Report onForm 8-K as Exhibits 99.1 and 99.2 and are incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| REPLIGEN CORPORATION | ||||||
| Dated: July 18, 2019 | By: | /s/ Tony J. Hunt | ||||
| Tony J. Hunt | ||||||
| President and Chief Executive Officer | ||||||